Xiaofeng Chen

Nov 15, 2024 | genomemedicine.biomedcentral.com | Tongpeng Xu |Tian Tian |Chen Wang |Xiaofeng Chen |Xiangrong Zuo |Hanyu Zhou | +9 more

This was a researcher-initiated, single-arm, open-label, single-center, first-in-human clinical trial (ChiCTR2100046544) designed to evaluate the safety and efficacy of KT032 in patients with mesothelin-expressing advanced solid tumors between August 2021 and February 2024, at the First Affiliated Hospital of Nanjing Medical University. Tumor biopsies were evaluated for mesothelin (MSLN) expression at enrolment, followed by leukapheresis and KT032 manufacture.

Jan 8, 2024 | mdpi.com | Wei Shen |Xiaofeng Chen |Yong Zhang |Xin Hu

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Dec 26, 2023 | preprints.org | Xiaofeng Chen

Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 16 December 2023 / Approved: 25 December 2023 / Online: 26 December 2023 (09:36:55 CET) Chen, X. Recent Computational Methods for Pathological Brain Detection. Preprints 2023, 2023121946. https://doi.org/10.20944/preprints202312.1946.v1 Chen, X. Recent Computational Methods for Pathological Brain Detection. Preprints 2023, 2023121946.